Objectives To review the surgical outcomes of cytoreductive surgery for ovarian cancer in a single institution.
Methods we reviewed all patients with ovarian cancer who received a cytoreductive surgery between January 2005 and December 2018 at Hôtel-Dieu de France University Hospital, Lebanon.
Results 161 patients were included. Mean age at surgery was 54 years (range 16 – 83 years). Cytoreductive surgery was done in four settings: upfront surgery (40%), interval surgery post neoadjuvant chemotherapy (42%), post recurrence (7%), post incomplete primary surgery (11%). 67% of operated patients were in stage III. Surgical resection included bowel resection (48%), diaphragmatic peritoneal resection (25%) and splenectomy (15%). 89% of patients received a pelvic and para-aortic lymphadenectomy. Node involvement was noted in 48% of cases. No recurrence was seen in 56% of cases and the mean interval of recurrence was estimated at 21 months with 78% of recurrences occurring after 12 months from surgery. Overall survival was estimated at 40 months (range 2 – 165 months). No impact on survival was detected whether the patient benefited from an upfront surgery or an interval one post neoadjuvant chemotherapy: 36 months vs 30 months respectively, (p= 0.39). Better survival was encountered when only one lymph node was involved (85 months vs 42 months, p=0.037).Patients with LNR ≤ 0.03 had a survival of 50 months vs. 27 months in patients with LNR > 0.03.
Conclusions Huge efforts including extensive cytoreductive surgeries are being performed at institutions in developing countries in order to improve survival and lower recurrence in ovarian cancer patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.